Insider Selling: Castle Biosciences (NASDAQ:CSTL) COO Sells $317,457.12 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,678 shares of the firm’s stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $25.04, for a total transaction of $317,457.12. Following the completion of the transaction, the chief operating officer directly owned 27,569 shares of the company’s stock, valued at $690,327.76. This represents a 31.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Castle Biosciences Price Performance

Shares of NASDAQ:CSTL opened at $33.55 on Friday. The company’s fifty day moving average is $23.88 and its two-hundred day moving average is $20.35. The company has a market cap of $979.32 million, a P/E ratio of -74.56 and a beta of 1.12. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $34.64. The company has a quick ratio of 6.69, a current ratio of 6.47 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. The business had revenue of $83.04 million for the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. Castle Biosciences has set its FY 2025 guidance at EPS. Equities analysts expect that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Several institutional investors and hedge funds have recently modified their holdings of CSTL. Allspring Global Investments Holdings LLC grew its holdings in Castle Biosciences by 2,070.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 217,794 shares of the company’s stock valued at $4,360,000 after purchasing an additional 207,761 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of Castle Biosciences by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 237,698 shares of the company’s stock worth $4,759,000 after buying an additional 60,161 shares during the period. Caxton Associates LLP acquired a new position in Castle Biosciences in the 1st quarter valued at $329,000. Cerity Partners LLC bought a new position in Castle Biosciences in the 1st quarter worth $423,000. Finally, Park West Asset Management LLC acquired a new position in Castle Biosciences during the 1st quarter worth $11,141,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CSTL. Robert W. Baird increased their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday, October 30th. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. BTIG Research boosted their price target on shares of Castle Biosciences from $32.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 10th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.43.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.